Overview
Mission Bio provides single-cell multi-omics technology that simultaneously detects SNVs, CNVs, and protein data from individual cells. The Tapestri Platform enables pharmaceutical and biotech companies to conduct precision genomics analysis for oncology research, biomarker development, cell and gene therapy, and genome editing safety assessment. Their pre-designed panels target genes implicated in hematologic malignancies and solid tumors, supporting drug development and therapeutic innovation.
Frequently asked questions
- What are Mission Bio's core capabilities for gene therapy development?
- Mission Bio's Tapestri Platform provides single-cell resolution analysis of gene edits, including measurement of predicted translocations, on-target and off-target editing, and chromosomal aberrations. This enables comprehensive safety assessment and design of more efficient and safer gene-editing therapeutics.
- What data types can Mission Bio detect simultaneously from a single cell?
- Mission Bio is the only multi-omics platform that simultaneously detects single nucleotide variants (SNVs), copy number variations (CNVs), and surface protein expression data from the same cell, enabling integrated genotypic and phenotypic analysis.
- What are the primary applications for pharmaceutical R&D?
- Key applications include oncology research (hematologic malignancies, solid tumors, AML MRD), precision medicine and biomarker development, cell and gene therapy development, genome editing assessment, and pharma assay development. The platform can detect rare subclones down to 0.1% that may be missed by bulk sequencing.
- What pre-designed panels does Mission Bio offer?
- Mission Bio provides a portfolio of pre-designed DNA panels covering the most commonly implicated genes in hematologic malignancies and solid tumors, enabling rapid analysis of genetic alterations across thousands of single cells.